logo
Harvard seeks billions in funding restored at a pivotal hearing in its standoff with Trump

Harvard seeks billions in funding restored at a pivotal hearing in its standoff with Trump

BOSTON (AP) — Lawyers for Harvard University argued in federal court Monday the Trump administration illegally cut $2.6 billion from the storied college — a pivotal moment in its battle against the federal government.
If U.S. District Judge Allison Burroughs decides in the university's favor, the ruling would reverse a series of funding freezes that later became outright cuts as the Trump administration
escalated its fight
with the nation's oldest and wealthiest university. Such a ruling, if it stands, would revive Harvard's sprawling scientific and medical
research operation
and hundreds of projects that lost federal money.
A lawyer for Harvard, Steven Lehotsky, opened the hearing by saying the Trump administration violated the university's First Amendment rights. He said the government conditioned research grants on Harvard 'ceding control' to the government over what is appropriate for students and faculty to say.
A second lawsuit over the cuts filed by the American Association of University Professors and its Harvard faculty chapter has been consolidated with the university's.
Harvard's lawsuit accuses President Donald Trump's administration of waging a retaliation campaign against the university after it rejected a series of demands in an April 11 letter from a federal antisemitism task force.
The letter demanded sweeping changes related to campus protests, academics and admissions. For example, the letter told Harvard to audit the viewpoints of students and faculty and admit more students or hire new professors if the campus was found to lack diverse points of view. The letter was meant to address government accusations that the university had become a hotbed of liberalism and tolerated anti-Jewish harassment on campus.
Harvard President Alan Garber pledged to fight antisemitism but said no government 'should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue.'
The same day Harvard rejected the demands, Trump officials moved to freeze $2.2 billion in research grants. Education Secretary Linda McMahon declared in May that Harvard would
no longer be eligible for new grants
, and weeks later the administration began
canceling contracts
with Harvard.
As Harvard fought the funding freeze in court, individual agencies began sending letters announcing that the frozen research grants were
being terminated
. They cited a clause that allows grants to be scrapped if they no longer align with government policies.
Harvard, which has the nation's largest endowment at $53 billion, has
moved to self-fund
some of its research, but warned it can't absorb the full cost of the federal cuts.
In court filings, the school said the government 'fails to explain how the termination of funding for research to treat cancer, support veterans, and improve national security addresses antisemitism.'
The Trump administration denies the cuts were made in retaliation, saying the grants were under review even before the April demand letter was sent. It argues the government has wide discretion to cancel contracts for policy reasons.
'It is the policy of the United States under the Trump Administration not to fund institutions that fail to adequately address antisemitism in their programs,' it said in court documents.
The research funding is only one front in Harvard's fight with the federal government. The Trump administration also has sought to prevent the school from
hosting foreign students
, and Trump has threatened to revoke Harvard's
tax-exempt status
.
Finally, last month, the Trump administration
formally issued a finding
that the school tolerated antisemitism — a step that eventually could jeopardize all of Harvard's federal funding, including federal student loans or grants. The penalty is typically referred to as a 'death sentence.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CNBC's Jim Cramer drops F-bomb live on air while marveling over Trump's ‘great economy'
CNBC's Jim Cramer drops F-bomb live on air while marveling over Trump's ‘great economy'

New York Post

time11 minutes ago

  • New York Post

CNBC's Jim Cramer drops F-bomb live on air while marveling over Trump's ‘great economy'

CNBC host Jim Cramer's excitement about President Donald Trump's latest trade deal got the better of him on Monday. Cramer blurted out 'What the f—!' during a segment of CNBC's 'Squawk on The Street' after seeing a graphic detailing the United States' recent trade deals with various countries, including a major trade deal made with the European Union on Sunday. 'Our biggest problem is we have so much growth that the Fed won't cut. What the f—!' the co-host exclaimed, regretting it as soon as he said it. 'Oh my God! I'm so sorry,' Cramer said. 'I'm so sorry. I take it right back. I take it right back. That was bad.' His co-hosts David Faber and Carl Quintanilla reassured their colleague it wasn't a big deal. 'It's OK. It's OK. It's OK!,' Faber told Cramer as he kept apologizing. 'We're in the moment. It's just the way we talk.' 4 Cramer blurted out 'What the f—!' during a segment of CNBC's 'Squawk on The Street'. MSNBC 'Real people doing live TV,' Quintanilla added. Cramer continued: 'I'm done. I think I'm out of here.' 'No, you're fine,' Faber replied, laughing. 'You're absolutely fine. You want me to say one?' Cramer said, 'No, I just feel like, enough with the rate cut and the economy's booming.' 4 'Oh my God! I'm so sorry,' Cramer said. 'I'm so sorry. I take it right back. I take it right back. That was bad.' REUTERS The anchor also apologized on X following the appearance. He wrote, 'I apologize to all viewers. I was too effusive in making my point about the great economy we have..' Trump averted a trade war and notched another win on Sunday. The president and European Commission President Ursula von der Leyen announced a trade deal between the U.S. and the European Union that set a 15-percent tariff on most EU goods imported into the U.S. 4 His co-hosts David Faber and Carl Quintanilla reassured their colleague it wasn't a big deal. MSNBC Von der Leyen said Europe will also purchase $150 billion worth of U.S. energy as part of the deal, in addition to making $600 billion in other investments. The agreement comes days after Trump secured a $550 billion trade deal with Japan. 'We just completed a massive Deal with Japan, perhaps the largest Deal ever made,' Trump wrote on Truth Social. 'Japan will invest, at my direction, $550 Billion Dollars into the United States, which will receive 90% of the Profits. This Deal will create Hundreds of Thousands of Jobs — There has never been anything like it.' 4 The agreement comes days after Trump secured a $550 billion trade deal with Japan. via REUTERS Some prominent critics of the president have admitted that they were wrong about the damage Trump's tariffs would do to the economy. Most recently, HBO host Bill Maher admitted on his 'Club Random' podcast that his predictions were incorrect. 'Just to take an example, tariffs. Now I remember that I, along with probably most people, was saying at the beginning, 'Oh, you know, by the 4th of July… the economy was going to be tanked by then,' and I was kind of like, 'Well, that seems right to me,'' he told guest, liberal pundit Brian Tyler Cohen. 'But, that didn't happen,' Maher said. 'It could happen tomorrow. I'm just saying, that's reality, so let's work first from the reality of that, not from 'I just hate Donald Trump,' because that's boring and doesn't get us anywhere and leads you to dishonesty.'

Judge Hit With Complaint Over Making 'Improper' Comments About Trump
Judge Hit With Complaint Over Making 'Improper' Comments About Trump

Newsweek

time12 minutes ago

  • Newsweek

Judge Hit With Complaint Over Making 'Improper' Comments About Trump

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Attorney General Pam Bondi announced a complaint filed by the Department of Justice (DOJ) against U.S. District Judge James E. Boasberg, appointee of former President Barack Obama, for "improper public comments" made about President Donald Trump and the administration. Newsweek reached out to a legal analyst via X, formerly Twitter, on Monday night for comment. Why It Matters Boasberg has been at the center of MAGA fury as he has presided over a case involving the Trump administration's speedy deportation of migrants through his invocation of the Alien Enemies Act of 1798. The act is a wartime law granting the commander in chief authority to detain or deport noncitizens. The implementation was blocked in federal court and has thus sparked a contentious legal back-and-forth with Boasberg, a chief judge. What To Know According to the Associated Press (AP), Boasberg's alleged remarks stem from comments he made to Supreme Court Chief Justice John Roberts and other federal judges that the Trump administration could trigger a constitutional crisis if they intentionally sidestep rulings. "Today at my direction, @TheJusticeDept filed a misconduct complaint against U.S. District Court Chief Judge James Boasberg for making improper public comments about President Trump and his Administration. These comments have undermined the integrity of the judiciary, and we will not stand for that," Bondi said on X. Boasberg's comments were reportedly made at a meeting of the Judicial Conference, as first reported by The Federalist, citing a memo obtained of the meeting. According to the AP, Bondi's complaint calls for Boasberg to be reassigned from the deportation case amid the investigation and possible impeachment if the allegations are substantiated. Trump previously called Boasberg a "troublemaker and agitator" and floated the suggestion of his impeachment earlier this year, prompting Roberts to issue a rare statement. "For more than two centuries, it has been established that impeachment is not an appropriate response to disagreement concerning a judicial decision. The normal appellate review process exists for that purpose," Roberts said. U.S. District Judge James Boasberg attends a panel discussion in Washington, D.C., on April 2 (Photo by DREW ANGERER/AFP via Getty Images) U.S. District Judge James Boasberg attends a panel discussion in Washington, D.C., on April 2 (Photo by DREW ANGERER/AFP via Getty Images) What Happens Next The complaint now awaits review by Chief Judge Sri Srinivasan and could be referred to a special investigative committee for further examination. Bigger questions about judicial independence, the limits of executive authority over immigration policy and the standards for disqualification or sanctioning of federal judges may also be shaped by the developments in this closely watched dispute.

South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk
South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk

Yahoo

time40 minutes ago

  • Yahoo

South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk

SEOUL (Reuters) -South Korean pharmaceutical firm Celltrion said on Tuesday that in an attempt to offset the risk of U.S. tariffs it had become the preferred bidder to acquire a U.S. manufacturing factory from an unnamed global pharmaceutical company. Celltrion's Founder and Chief Executive Seo Jung-jin told a briefing it planned to invest 700 billion won ($503.78 million) in the acquisition and operation of the factory, without giving a breakdown of the figure. The company could make an additional investment ranging from 300 billion won to 700 billion won depending on U.S. tariff policy. The U.S. has been conducting a national security investigation into the pharmaceutical sector and President Donald Trump said earlier this month that pharmaceutical tariffs could be as high as 200%. He expected the tariffs to offer "opportunities" by increasing drug prices and reducing competition, thus improving profitability. Celltrion said it would not disclose further details, including the name of the seller and its location, until the signing of the final agreement, which is expected in early October.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store